natgillin/translations-raw huggingface dataset:
Fluticasone furoate nasal spray 110 micrograms once daily significantly improved ocular symptoms as well as improving patients’ disease-related quality of life (RQLQ) compared to placebo in one study.
V primerjavi s placebom je flutikazonfuroat v obliki pršila za nos v odmerku 110 mikrogramov enkrat na dan v eni študiji pomembno izboljšal tako očesne simptome kot tudi z boleznijo povezano kakovost življenja bolnika (RQLQ).
Fluticasone furoate nasal spray significantly improved the patients’ perception of overall response to therapy, and the patients’ disease-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire – RQLQ), in all 4 studies.
Flutikazonfuroat v obliki pršila za nos je v vseh 4 študijah pomembno izboljšal bolnikov vtis o celotnem odzivu na zdravljenje in z boleznijo povezano kakovost življenja bolnika (vprašalnik o kakovosti življenja z rinokonjunktivitisom; “Rhinoconjunctivitis Quality of Life Questionnaire” – RQLQ).
Fluticasone furoate or vilanterol has no or negligible influence on the ability to drive and use machines.
Flutikazonfuroat in vilanterol nimata vpliva ali imata zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Fluticasone furoate was not genotoxic in a standard battery of studies and was not carcinogenic in lifetime inhalation studies in rats or mice at exposures similar to those at the maximum recommended human dose, based on AUC.
Flutikazonfuroat ni bil genotoksičen v standardni skupini študij in ni bil kancerogen v študijah vseživljenjskega vdihavanja pri podganah ali miših pri izpostavljenostih, podobnih kot so izpostavljenosti (na podlagi AUC) med uporabo največjega priporočenega odmerka za človeka.
fluticasone furoate/ vilanterol 92/22 (n=403)
flutikazonfuro at/vilanterol 92/22 (n =
fluticasone furoate/ vilanterol 92/22 (n=403)
flutikazonfuro at/vilanterol 92/22 (n = 403)
Fluticasone furoate/vilanterol 92/22 micrograms consistently demonstrated 83 mL to 95 mL improvements in trough FEV1 at weeks 12, 36 and 52 and Endpoint compared with FF 92 micrograms (p<0.001 95% CI 52, 126 mL at Endpoint).
Flutikazonfuroat/vilanterol 92/22 mikrogramov je v primerjavi z 92 mikrogrami FF dosledno dosegal izboljšanje najnižjega FEV1 za 83 do 95 ml 12., 36. in 52. teden ter na končni točki študije (p < 0,001 95 % IZ od 52 do 126 ml na končni točki).
Fluticasone furoate/vilanterol 92/22 micrograms increased adjusted mean weighted mean FEV1 over 0-4 hours by 148 ml compared to FF alone (95% CI: 112, 184 mL, p< 0.001).
Flutikazonfuroat/vilanterol 92/22 mikrogramov je v primerjavi s samim FF povečal korigirani povprečni uteženi FEV1 v obdobju 0-4 ure za 148 ml (95 % IZ: 112, 184 ml, p < 0,001).
Fluticasone furoate/vilanterol should not be used to treat acute asthma symptoms, for which a short-acting bronchodilator is required.
Flutikazonfuroat/vilanterol se ne sme uporabljati za zdravljenje simptomov akutne astme ali akutnega poslabšanja KOPB; za to je potreben kratkodelujoč bronhodilatator.
fluticasone particularly
flutikazona, zlasti
Fluticasone propionate
Flutikazonproprionat
Fluticasone propionate
INHALACIJSKI NAZALNI KORTIKOSTEROIDI
Fluticasone propionate aqueous nasal spray 200 µg qd 100 q12h ↑ ~350-fold ↑ ~ 25-fold
Flutikazonijev propionat, vodno pršilo za nos 200 µg na dan 100 na 12 ur ↑ ~350-krat ↑ ~ 25-krat
Fluticasone propionate intranasal 50 µg 4 times daily for 7 days (ritonavir 100 mg capsules twice daily)
Flutikazonpropionat za intranazalno uporabo 50 µg 4- krat na dan, 7 dni (ritonavir 100 mg kapsule dvakrat na dan)
Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs.
Flutikazonpropionat je kortikosteroid, ki zmanjšuje otekanje in draženje v pljučih.
Fluticasone propionate,
Flutikazonpropionat,
Fluticasone propionate:
Flutikazonproprionat:
Fluticasone propionate:
Med vdihavanjem
Fluticasone propionate: 
flutikazon propionat
fluticasone systemic
Intrinzična raven kortizola:
fluticasone, a medicine used to treat hay fever and asthma
flutikazon; zdravilo, ki se uporablja za zdravljenje senenega nahoda in astme
fluticasone.
ritonavirjem
fluvastatin (used to treat high cholesterol),
fluvastatin (uporablja se za zdravljenje visokega holesterola),
fluvastatin and pitavastatin
fluvastatinom in
Fluvastatin Pitavastatin Pravastatin
atorvastatin fluvastatin pitavastatin pravastatin
Fluvastatin, and rosuvastatin are
Fluvastatin in
Fluvoxamine (used for the treatment of depression and obsessive compulsive disorder), psoralens (used in the treatment of skin disorders e.g. psoriasis), cimetidine (used in the treatment of stomach problems such as ulcers), quinolones and rifampicin (used in the treatment of bacterial infections), oestrogens (used in contraceptives or hormone replacement therapy) and carbamazepine (used in the treatment of epilepsy).
fluvoksamin (uporablja se za zdravljenje depresije in obsesivne kompulzivne motnje), psoraleni (za zdravljenje kožnih bolezni, npr. luskavice), cimetidin (za zdravljenje želodčnih težav, kot so razjede), kinoloni in rifampicin (za zdravljenje bakterijskih okužb), estrogeni (v kontracepcijskih sredstvih in nadomestnem hormonskem zdravljenju) ter karbamazepini (za zdravljenje epilepsije).
Fluvoxamine, a potent CYP1A2 and moderate CYP2C9 inhibitor markedly inhibits the metabolism of agomelatine resulting in a 60-fold (range 12-412) increase of agomelatine exposure.
Fluvoksamin, močan zaviralec CYP1A2 in zmeren zaviralec CYP2C9, izrazito zavira presnovo agomelatina, zaradi česar se izpostavljenost agomelatinu zveča za 60-krat (razpon: 12-krat do 412-krat).
Fluvoxamine, used to treat depression;
fluvoksamin za zdravljenje depresij;
FMD antigen ≥ 6 cattle PD50 per strain
FMD antigen ≥ 6 PD50 za govedo na sev
FN was associated with dose interruption in 3.7% of patients, and with dose reduction in 1.3% of patients, and with no treatment discontinuations.
FN je bila pri 3,7 % bolnikov povezana s prekinitvijo odmerka, in pri 1,3 % bolnikov z zmanjšanjem odmerka in pri nobenem z ukinitvijo zdravljenja.
Foam looks like a mass of small bubbles that float as a layer to the top of the liquid.
Pene izgledajo kot gmota majhnih mehurčkov, ki se v plasti dvigujejo na gladino.
Foamy urine
penast urin,
foamy urine
penjenje urina,
Focal hepatic steatosis (1)
fokalna steatoza jeter (1)
Focal Score
Fokalni seštevek
Focetria contains small amounts of ‘surface antigens’ (proteins
Zdravilo Focetria vsebuje majhne količine
Focetria injection Influenza vaccine H1N1v Intramuscular use
Focetria injekcija cepivo proti gripi H1N1v intramuskularna uporaba
Focetria injection Influenza vaccine H1N1v Intramuscular use.
Focetria injekcija cepivo proti gripi H1N1v intramuskularna uporaba
Focetria is a milky-white liquid.
Cepivo Focetria je mlečno bela tekočina.
Focetria is a vaccine to prevent influenza (flu) caused by A(H1N1v) 2009 virus.
Cepivo Focetria je cepivo za preprečevanje gripe, ki jo povzroča virus A(H1N1v) 2009.
Focetria may be administered to lactacting women.
S cepivom Focetria se lahko cepi doječe ženske.
Focetria may be administered to lactating women.
S cepivom Focetria se lahko cepi doječe ženske.
Focetria was originally authorised under ‘exceptional circumstances’, because, for scientific reasons, limited information was available at the time of approval.
Zdravilo Focetria je bilo prvotno odobreno v „izjemnih okoliščinah“, saj so bile zaradi znanstvenih razlogov ob odobritvi na voljo le omejene informacije.
Foclivia can only be marketed when there is an official WHO/EU declaration of an influenza pandemic, on the condition that the Marketing Authorisation Holder for Foclivia takes due account of the officially declared pandemic strain.
Zdravilo Foclivia se lahko trži samo, kadar SZO/EU uradno razglasi pandemijo gripe, pod pogojem, da imetnik dovoljenja za promet z zdravilom Foclivia upošteva uradno razglašen pandemični sev.
Foclivia has been authorised under ‘exceptional circumstances’.
Zdravilo Foclivia je pridobilo dovoljenje za promet v „izjemnih okoliščinah“.
Foclivia is a vaccine that can only be used once a flu ‘pandemic’ has been officially declared by the World Health Organization (WHO) or the European Union (EU).
Zdravilo Foclivia je cepivo, ki se lahko uporablja šele potem, ko Svetovna zdravstvena organizacija (WHO) ali Evropska unija (EU) uradno razglasi pandemijo gripe.
Foclivia is a vaccine.
Zdravilo Foclivia je cepivo.
Foclivia is given in two doses, at least three weeks apart.
Zdravilo Foclivia se daje v dveh odmerkih v razmiku najmanj treh tednov.
Foclivia pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
Foclivia pandemsko cepivo proti gripi (H5N1) (s površinskimi antigeni, inaktivirano, z adjuvansom)
Foclivia should not be given at the same time as other vaccines.
Zdravilo Foclivia se ne sme dajati sočasno z drugimi cepivi.
Foclivia should not be given to patients who have had an anaphylactic reaction (severe allergic reaction) to any of the components of the vaccine, or to any substances found at trace levels in the vaccine, such as eggs, chicken protein, kanamycin or neomycin sulphate (two antibiotics), formaldehyde, barium sulphate and cetyltrimethylammonium bromide (CTAB).
Cepivo Foclivia se ne sme dajati osebam, ki so imele v preteklosti anafilaktično reakcijo (hudo alergijsko reakcijo) na katero koli izmed sestavin cepiva ali na katero koli od snovi, ki se v sledovih nahajajo v cepivu, kot na primer na jajca, piščančje beljakovine, kanamicin ali neomicinsulfat (dva antibiotika), formaldehid, barijev sulfat in cetiltrimetilamonijev bromid (CTAB).
Foclivia suspension for injection
Foclivia suspenzija za injiciranje
Foclivia suspension for injection in multidose container
Foclivia suspenzija za injiciranje v vsebniku z več odmerki.
Foclivia suspension for injection in pre-filled syringe
Foclivia suspenzija za injiciranje v napolnjeni injekcijski brizgi
Foclivia was evaluated in adults aged (18 to 60 years old) and elderly (over 60 years old) following a 1, 22 day primary vaccination schedule.
Zdravilo Foclivia je bilo ocenjeno pri odraslih (starih od 18 do 60 let) in starejših bolnikih (starih več kot 60 let) po razporedu primarnega cepljenja 1., 22. dan.
Foclivia would be given according to official recommendations.
Zdravilo Foclivia se daje v skladu z uradnimi priporočili.
Foetal abnormalitiesa,b
nenormalnosti plodaa,b
Foetal exposure in the rats and rabbits was approximately 15 to 20 % of that of the mother.
Izpostavljenost zarodka pri podganah in kuncih je bila približno 15 do 20 % materine izpostavljenosti.
Foetal exposure to bosutinib-derived radioactivity during pregnancy was demonstrated in a placental transfer study in gravid Sprague-Dawley rats.
Izpostavljenost ploda radioaktivno označenemu bosutinibu med nosečnostjo je bila dokazana v študiji prenosa prek posteljice na brejih Sprague-Dawley podganah.
Foetal growth restriction was apparent in animal studies with pioglitazone.
Pri študijah pioglitazona na živalih so opazili omejitev rasti plodov.
Foetal growth restriction was apparent in animal studies with pioglitazone.
Pri študijah pioglitazona na živalih so opažali zastoj rasti ploda.
Foggy feeling in head
meglen občutek v glavi
FOIL - For all pack sizes
FOLIJA- za vse velikosti pakiranja
FOIL 0.67ml
FOLIJA 0,67 ml
FOIL 0.80ml for small cats
FOLIJA 0,80 ml
FOIL 1.33ml
FOLIJA 1.33 ml
FOIL 1.60 ml for large cats
FOLIJA 1.60 ml
FOIL 3.33ml
FOLIJA 3.33 ml
FOIL 5.33ml
FOLIJA 5.33 ml
FOIL 6.66ml
FOLIJA 6.66 ml
FOIL LABEL, 15 mg, 30 mg, 45 mg, 60 mg, 120 mg, 240 mg, 360 mg
Merilna kapalka, 15 mg,30 mg, 45 mg, 60 mg, 120 mg, 240mg, 360 mg
FOIL OVERWRAP
PREKRIVNA FOLIJA
FOIL POUCH
VREČKA IZ FOLIJE
Foil Sachet (5.1 cm x 10.2 cm)
Vrečka iz folije (5,1 cm x 10,2 cm)
Foil-bag containing 1, 3 or 5 continuous-release intraruminal devices
Vrečka iz folije, ki vsebuje 1, 3 ali 5 intraruminalnih sistemov s kontinuiranim sproščanjem
foil/PVC blister
pretisni omot
foil/PVC blisters
pretisni omot
fold increase in midazolam plasma levels.
plazemskih koncentracij midazolam.
Fold increase in peripheral blood CD34+ cell count following Mozobil administration
N-kratno povečanje celic CD34+ v periferni krvi po prejetju zdravila Mozobil
Fold out
Razprite
Fold out (Notes information)
Razprite (Opomba)
Fold the hydrogel housing in half with the sticky side facing in.
Zložite hidrogelno ohišje na pol, z lepilno stranjo obrnjeno navznoter.
Fold the needle guard out of the way of the needle cover.
Upognite varovalni nastavek proč od pokrovčka igle.
Fold the skin lightly and insert the injection needle completely at a 45° to 90° angle using a dart-like motion.
Nežno stisnite kožno gubo in iglo popolnoma vstavite pod kotom od 45 ° do 90 °, pri čemer uporabite sunkoviti gib.
Fold the used patch in half, sticking the patch to itself, and discard it in a safe way in order to keep it away from children (e.g. in a rubbish bin).
Uporabljeni obliž prepognite, tako da se zalepi sam nase in ga zavrzite na varen način, tako da bo zunaj dosega otrok (npr. v koš za smeti).
Fold wings down along the intraruminal device body and insert the intraruminal device into an appropriate administration tool, orifice end first.
Krilca zapognite navzdol vzdolž telesa intraruminalnega sistema in sistem vstavite v ustrezno orodje za dajanje zdravila, z ustjem naprej.
FOLDING BOX
ŠKATLA
FOLDING BOX AND LABEL FOR BOTTLE for 110 mg
ŠKATLA/ZUNANJA IN NALEPKA ZA PLASTENKO po 110 mg
FOLDING BOX AND LABEL FOR BOTTLE for 150 mg
ŠKATLA/ZUNANJA IN NALEPKA ZA PLASTENKO po 150 mg
FOLDING BOX AND LABEL FOR BOTTLE for 75 mg
ŠKATLA/ZUNANJA IN NALEPKA ZA PLASTENKO po 75 mg
FOLDING BOX FOR 1 VIAL AS UNIT PACK (INCLUDING BLUE BOX) FOLDING BOX FOR 4 VIALS AS UNIT PACK (INCLUDING BLUE BOX)
ŠKATLA ZA 1 VIALO KOT ENOTA PAKIRANJA (VKLJUČENI PODATKI ZA “BLUE BOX”) ŠKATLA ZA 4 VIALE KOT ENOTA PAKIRANJA (VKLJUČENI PODATKI ZA “BLUE BOX”)
FOLDING BOX FOR 4 [10] VIALS AS UNIT PACK (INCLUDING BLUE BOX)
ŠKATLA ZA 4 VIALE / [10] VIAL KOT ENOTA PAKIRANJA (VKLJUČENI PODATKI ZA “BLUE BOX”)
FOLDING BOX FOR BLISTER for 110 mg
ŠKATLA ZA PRETISNI OMOT po 110 mg
FOLDING BOX FOR BLISTER for 150 mg
ŠKATLA ZA PRETISNI OMOT po 150 mg
FOLDING BOX FOR BLISTER for 75 mg
ŠKATLA ZA PRETISNI OMOT po 75 mg
FOLDING BOX – INTERMEDIATE CONTAINER OF MULTIPACK (WITHOUT BLUE BOX)
ŠKATLA - VMESNI VSEBNIK SKUPNEGA PAKIRANJA (BREZ "BLUE BOX" PODATKOV)
FOLDING BOX – OUTER CONTAINER OF MULTIPACK (WITH BLUE BOX)
ŠKATLA - ZUNANJI VSEBNIK SKUPNEGA PAKIRANJA (Z "BLUE BOX" PODATKI)
Folding carton containing a HDPE bottle (15 ml oral suspension)
Zloženka s HDPE plastenko (15 ml peroralne suspenzije)
Folding carton containing a HDPE bottle (30 ml oral suspension)
Zloženka s HDPE plastenko (30 ml peroralne suspenzije)
FOLFIRI
(N=246) (N=214)
FOLFIRI (N=528)
FOLFIRI (N = 528)
FOLFIRI (N=529)
FOLFIRI (N = 529)
FOLFIRI chemotherapy is given by intravenous infusion, after the Cyramza infusion has finished.
Kemoterapija FOLFIRI se daje z intravensko infuzijo po zaključku infuzije zdravila Cyramza.
FOLFIRI dose adjustments
Prilagajanje odmerkov sheme FOLFIRI
FOLFIRI Dose modification when used in combination with ZALTRAP
Prilagoditev odmerka FOLFIRI med uporabo v kombinaciji z zdravilom ZALTRAP
FOLFOX-4
FOLFOX-4 ali FOLFOX-4 +
FOLFOX-4 or FOLFOX-4 +
FOLFOX-4 ali FOLFOX-4 +
FOLFOX-4 or XELOX
FOLFOX-4 ali XELOX
FOLFOX-4  Avastina
FOLFOX-4
FOLFOX-4/FOLFOX-4+P/ FOLFOX-4+BV (EPP*: N = 937; ITT**: N= 1017)
(EPP*: n = 937; ITT**: n = 1.017)
folinic acid (often used in chemotherapy with methotrexate)
folno kislino (pogosto se uporablja pri kemoterapiji z metotreksatom);
Follicular lymphoma (also called “FL”)
Folikularnega limfoma (FL)
Follicular Lymphoma (FL)
Folikularni limfom
follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer) chronic lymphocytic leukaemia (CLL, another blood cancer affecting white blood cells)
folikularnega limfoma in difuznega velikoceličnega B ne-Hodgkinovega limfoma (dveh vrst ne- Hodgkinovega limfoma, krvnega raka); kronične limfocitne levkemije (KLL, drugega krvnega raka, ki prizadene bele krvničke);
Follicular versus non-follicular was also a stratification factor for the study but is not applicable in the subgroup analysis of patients with follicular lymphoma.
Stratifikacijski dejavnik v študiji je bila tudi folikularna bolezen v primerjavi z nefolikularno, vendar ta dejavnik ne pride v poštev za analizo podskupin bolnikov s folikularnim limfomom.
Folliculitis, fungal infection, cold sores (non-herpetic), upper respiratory tract infection
folikulitis, glivične okužbe, razjede (neherpetične), okužba zgornjih dihal
Follitropin alfa in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency.
Folitropin alfa se priporoča skupaj z luteinizirajočim hormonom (LH) za spodbujanje razvoja foliklov pri ženskah s hudim pomanjkanjem LH in FSH.
Follitropin alfa is a potent gonadotrophic substance capable of causing mild to severe adverse reactions, and should only be used by physicians who are thoroughly familiar with infertility problems and their management.
Folitropin alfa je močna gonadotropna učinkovina, ki lahko povzroči blage do hude neželene reakcije, zato ga smejo uporabljati samo zdravniki, ki dobro poznajo težave neplodnosti in njihovo obvladovanje.
Follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human Chorionic Gonadotrophin (hCG) therapy.
Folitropin alfa je s sočasnim zdravljenjem s humanim horionskim gonadotropinom (hCG) indiciran za stimulacijo spermatogeneze pri moških, ki imajo prirojen ali pridobljen hipogonadotropni hipogonadizem.
Follitropin alfa may be given as a course of daily injections.
Folitropin alfa se lahko daje kot zaporedje dnevnih injekcij.
Follitropin alfa must not be used when an effective response cannot be obtained, such as:
Folitropina alfa ne smete uporabljati, kadar ni mogoče doseči učinkovitega odziva, kot je npr.:
Follitropin beta may affect milk production.
Folitropin beta lahko vpliva na nastajanje mleka.
Follow all instructions given to you by your doctor and pharmacist carefully, even if they are different from what is in this leaflet.
Skrbno se ravnajte po vseh navodilih, ki vam jih je dal vaš zdravnik ali farmacevt, tudi če se razlikujejo od informacij v tem navodilu za uporabo.
Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given Zoledronic acid Teva Generics.
Skrbno se ravnajte po vseh navodilih zdravnika, farmacevta ali medicinske sestre, preden vam dajo zdravilo Zoledronska kislina Teva Generics.
Follow all steps in Section 2.
Sledite vsem korakom, opisanim v 2. poglavju.
Follow all the doctor’s instructions carefully.
Skrbno se držite njegovih navodil.
Follow all the doctor’s instructions carefully.
Skrbno se držite zdravnikovih navodil.
Follow all the doctor’s instructions carefully.
Skrbno se ravnajte po vseh navodilih vašega zdravnika.
Follow all your doctor’s instructions carefully, even if they differ from the general information contained in this leaflet.
Skrbno se ravnajte po vseh navodilih svojega zdravnika, tudi če se razlikujejo od splošnih informacij v tem navodilu za uporabo.
Follow all your doctor’s instructions carefully, even if they differ from the general information contained in this leaflet.
Skrbno se ravnajte po vseh navodilih vašega zdravnika, tudi če se razlikujejo od splošnih informacij v tem navodilu za uporabo.
Follow carefully all instructions given by your doctor or nurse.
Skrbno se ravnajte po vseh navodilih, ki vam jih da vaš zdravnik ali medicinska sestra.
Follow carefully all instructions given to you by your doctor or nurse.
Skrbno se ravnajte po vseh navodilih, ki vam jih je dal vaš zdravnik ali medicinska sestra.
Follow carefully any instructions that come with the nebuliser.
Skrbno upoštevajte navodila, ki so priložena nebulatorju.
Follow carefully the instructions that come with the nebuliser especially the instructions on hygiene and cleaning of the nebuliser.
Natančno upoštevajte navodila priložena nebulatorju, predvsem navodila za nego in čiščenje nebulatorja.
Follow carefully the instructions that come with the nebuliser especially the instructions on hygiene and cleaning of the nebuliser.
Natančno upoštevajte navodila, priložena nebulatorju, predvsem navodila za nego in čiščenje nebulatorja.
Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.
Natančno upoštevate navodila za odmerjanje, nadziranje bolezni (testi krvi in urina), prehrano in telesno dejavnost (telesno delo in telovadbo), ki vam jih je dal zdravnik.
Follow directions carefully.
Skrbno upoštevajte navodila.
Follow instructions to twist the cartridge until ‘2’ appears in the number window and a “click” is heard.
Sledite navodilom in zasučite vložek, dokler se v številskem okencu ne pojavi "2" in zaslišite klik.
Follow recommended safety measures for removal and disposal of needles (contact your doctor, pharmacist or nurse) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Upoštevajte priporočene varnostne ukrepe za odstranjevanje in odlaganje igel (obrnite se na zdravnika, farmacevta ali medicinsko sestro), da boste zmanjšali tveganje za naključno poškodbo z iglo in prenos nalezljivih bolezni.
Follow recommended safety measures for removal and disposal of needles (e.g. contact your doctor, pharmacist or nurse) in order to reduce the risk of accidental needle injury and transmission of infectious diseases.
Upoštevajte priporočene varnostne ukrepe, ko igle odstranjujete in zavržete (posvetujte se s svojim zdravnikom, s farmacevtom ali z medicinsko sestro), da boste zmanjšali tveganje za naključno poškodbo z iglo in prenos nalezljivih bolezni.
Follow Section 2 only to set up a new pen before first use.
Sledite Poglavju 2 samo za pripravo novega injekcijskega peresnika pred prvo uporabo.
Follow the directions given by your doctor closely and use the detailed instructions for reconstitution and administration provided at the end of this leaflet
Natančno upoštevajte navodila zdravnika in podrobnejša navodila za rekonstitucijo in uporabo zdravila, ki so na koncu tega navodila.
Follow the directions given by your doctor closely and use the detailed instructions for reconstitution and administration provided at the end of this leaflet
Pri uporabi zdravila natančno upoštevajte navodila zdravnika in podrobnejša navodila za rekonstitucijo in uporabo, ki jih najdete na koncu tega navodila.
Follow the directions given by your doctor closely and use the instructions below as a guide:
Pri uporabi zdravila natančno upoštevajte navodila zdravnika in naslednje navodilo za pripravo in uporabo:
Follow the doctor’s instructions for throwing away the needle and syringe.
Uporabljeno injekcijsko iglo in brizgo zavrzite v skladu z navodili zdravnika.
Follow the injection procedure as instructed by your doctor.
Pri tem se držite navodil za injiciranje, ki ste jih dobili od svojega zdravnika.
Follow the instructions and recommendations from your doctor regarding the use of Velosulin in a pump.
Upoštevajte zdravnikova navodila in priporocila o uporabi zdravila Velosulin v crpalki.
Follow the instructions below to expel the excess volume before injection.
Sledite spodnjim navodilom za odstranitev odvečnega volumna pred injiciranjem.
Follow the instructions below to prepare and administer Imlygic to patients:
Za pripravo in dajanje zdravila Imlygic bolnikom sledite spodnjim navodilom:
Follow the instructions for hygienic injection technique recommended by your healthcare professional.
Sledite navodilom o higienski tehniki injiciranja, ki jo priporoča vaš zdravstveni delavec.
Follow the instructions for proper use for your connector and CVAD in consultation with your doctor or nurse.
Upoštevajte navodila za pravilno uporabo
Follow the instructions for sanitary injection technique recommended by your healthcare professional.
Sledite navodilom za pravilne tehnike injiciranja, ki jih priporoča vaše zdravstveno osebje.
Follow the instructions given to you by your doctor.
Upoštevajte zdravnikova navodila.